Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patients in the PALISADE study, a Phase III clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS).
The Medicines and Healthcare products Regulatory Agency has announced that IONIS APOC IIIRx (volanesorsen), from Akcea Therapeutics, will be available...
Akcea Therapeutics, Inc an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. announced that they received a Complete Response...
The National Institute for Health and Care Excellence (NICE) has issued an Evaluation Consultation Document (ECD), refusing Waylivra (volanesorsen) as...
Akcea Therapeutics, Inc.,an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. announced that Waylivra has received conditional marketing authorization...
Abbott has announced the FDA approved the Masters HP 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve,...
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. focused on developing and commercializing drugs to treat patients with serious...
On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Agilus, intended for the treatment of malignant hyperthermia in combination with adequate support measures.The applicant for this medicinal product is Norgine B.V.